ストックスクリーナーアプリを入手
1.89
0.53%
0.01
アフターアワーズ：
1.85
-0.04
-2.12%
前日終値:
$1.88
開ける：
$1.9
24時間の取引高:
320.87K
Relative Volume:
0.31
時価総額：
$80.40M
収益：
-
当期純損益:
$-40.92M
株価収益率:
-1.1009
EPS:
-1.7167
ネットキャッシュフロー:
$-26.53M
1週間 パフォーマンス:
+9.88%
1か月 パフォーマンス:
+1.61%
6か月 パフォーマンス:
-21.25%
1年 パフォーマンス:
-25.88%
1日の値動き範囲:
$1.85
$1.90
1週間の範囲:
$1.72
$1.976
52週間の値動き範囲:
$1.5407
$5.50
Annovis Bio Inc Stock (ANVS) Company Profile
名前
Annovis Bio Inc
セクター
電話
484-875-3192
住所
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
1.89 | 71.04M | 0 | -40.92M | -26.53M | -1.7167 |
VRTX
Vertex Pharmaceuticals Inc
|
523.91 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
808.05 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
866.11 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.97 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
359.00 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-10 | ダウングレード | D. Boral Capital | Buy → Hold |
| 2024-10-25 | アップグレード | Maxim Group | Hold → Buy |
| 2023-12-29 | 開始されました | Canaccord Genuity | Buy |
| 2021-07-07 | 繰り返されました | Maxim Group | Buy |
Annovis Bio Inc (ANVS) 最新ニュース
ANVS|Annovis Bio Inc|Price:1.665|Chg%:+0.005 - TradingKey
Annovis Bio Inc (ANVS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Annovis Bio Inc (ANVS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Annovis Bio Inc (ANVS) Institutional Confidence - TradingKey
Annovis Bio Inc (ANVS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Annovis Bio Inc (ANVS) Cash Flow - TradingKey
Annovis Bio Inc (ANVS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Annovis Bio Inc (ANVS) Income Statement - TradingKey
Annovis Bio Inc (ANVS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Annovis Bio Inc (ANVS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ANVS|Annovis Bio Inc|Price:1.650|Chg%:-0.100 - TradingKey
ANVS|Annovis Bio Inc|Price:1.686|Chg%:+0.026 - TradingKey
Annovis Bio Inc (ANVS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Annovis Bio Inc (ANVS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Annovis Bio, Inc. Revenue Breakdown – NYSE:ANVS - TradingView
ANVS stock holds support after recent clinical update - Ad-hoc-news.de
Annovis Completes Enrollment for Alzheimer’s Phase 3 Trial - MyChesCo
Annovis Bio enrolls over 850 patients for its next Alzheimer's Disease trial - qz.com
Annovis Bio Completes Enrollment for Pivotal Phase 3 Alzheimer’s Trial, Plans NDA Submissions in 2027 and 2028 12 - Minichart
Annovis Bio Completes Enrollment in Pivotal Alzheimer’s Trial - TipRanks
Annovis Reaches Full Enrollment in Phase 3 Buntanetap Trial, 850 Patients Enrolled - TradingView
Annovis Bio (NYSE: ANVS) completes enrollment in 850-patient Phase 3 Alzheimer’s study - Stock Titan
Roth MKM Maintains Annovis Bio(ANVS.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Analysts’ Top Healthcare Picks: Evolus (EOLS), Annovis Bio (ANVS) - The Globe and Mail
Annovis Promotes Research Chief as Lead Drug Nears Key Trial - MyChesCo
Roth MKM Initiates Annovis Bio(ANVS.US) With Buy Rating, Announces Target Price $8 - Moomoo
Annovis Bio Enrolls Over 850 Patients for Its Next Alzheimer's Disease Trial - Yahoo Finance
The timeline for the key clinical trial data readout of Annovis Bio Inc. has been clarified. - Bitget
Annovis Bio completes enrollment in phase 3 Alzheimer’s trial By Investing.com - Investing.com Australia
Annovis Bio Completes Patient Enrollment for Phase 3 Study of Buntanetap in Alzheimer's Disease - Moomoo
Annovis Bio completes enrollment in phase 3 Alzheimer’s trial - Investing.com
Annovis Reaches Full Enrollment in Pivotal Phase 3 Trial of Buntanetap for Early Alzheimer’s Disease - GlobeNewswire
The buntanetap programAnnovis Bio bets on neurodegeneration trials - ad-hoc-news.de
Annovis Bio promotes Cheng Fang to chief scientific officer By Investing.com - Investing.com Australia
Annovis Bio promotes Cheng Fang to chief scientific officer - Investing.com
Annovis Bio Promotes Cheng Fang to Chief Scientific Officer Ahead of Phase 3 Milestones - citybiz
Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer - The Manila Times
Press Release: Annovis Appoints Cheng Fang, Ph.D., as Chief Scientific Officer - Moomoo
ANVSAnnovis Bio Inc Latest SEC Filings - Finviz
ANVS Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Revenue Biotech Advances PipelineAnalyst Consensus Shift - dars.gov.et
Annovis Bio, Inc.(NYSE: ANVS) added to Russell 3000E Growth Benchmark - marketscreener.com
Annovis Bio, Inc.(NYSE: ANVS) added to Russell 3000E Index - marketscreener.com
Annovis Bio, Inc.(NYSE: ANVS) added to Russell Microcap Index - marketscreener.com
ANVS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Annovis Bio, Inc.(NYSE: ANVS) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Annovis Bio (ANVS) Shows Resilience With 4.24% Gain, Testing Key ResistanceBeta Neutral Pair - dars.gov.et
Annovis Bio | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
Annovis Bio Inc Actuals & Estimates (TRADEGATE:07X) - TradingView
Annovis Bio | DEFA14A: Others - Moomoo
ANVS Forecast — Price Target — Prediction for 2027 - TradingView
Annovis Bio Inc Actuals & Estimates (FWB:07X) - TradingView
Annovis Bio Inc (ANVS) 財務データ
収益
当期純利益
現金流量
EPS
Annovis Bio Inc (ANVS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Hoffman Michael B | Director |
Apr 02 '26 |
Buy |
2.10 |
713,800 |
1,498,980 |
3,288,539 |
0.82%
1.54%
大文字化:
|
ボリューム (24 時間):